BioAffinity Technologies received a key Hong Kong patent for its CyPath Lung diagnostic, complementing an existing China patent. This expands intellectual property protection in a high-incidence lung cancer region, driving a significant surge in the company's stock and warrants.
BioAffinity Technologies announced the grant of a Hong Kong patent for its CyPath Lung diagnostic, a noninvasive tool for assessing lung nodules. This patent, combined with a 2025 patent in China, establishes dual intellectual property protection in a region that accounts for nearly two-thirds of global lung cancer cases. The news is highly significant for the company as it strengthens its market position and potential for commercialization in a critical market. The immediate impact is a substantial surge in BIAF stock and its warrants (BIAFW), indicating strong investor confidence in the expanded IP moat. Long-term, this could lead to increased adoption and revenue for CyPath Lung, but execution and market penetration remain key challenges.